retatrutide and heart issues Since January 2026, there have been six cases of acute liver toxicity associated with unapproved peptide products labelled in Australia. These toxic effects may be linked to a contaminant in the A study of Lilly's retatrutide

China Could Approve Lilly's Oral GLP-1 Weight-Loss Pill as Early as 2026, Executive Says What's Happening Eli Lilly expects China could approve its experimental oral GLP-1 obesity treatment as early as 2026, according to a company executive

It was like my body was learning to be content without constantly snacking or overeating

We are excited about the future of Retatrutide and look forward to making these new treatments available to our patients

The result is a compound that simultaneously reduces caloric intake, improves insulin sensitivity, and accelerates fat oxidation

With every discovery through clinical studies, we can offer more people the chance for a healthier future.